NivolumabPsoriasis following an off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1717卷 / 1期

关键词：

D O I：

10.1007/s40278-018-51284-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：214 / 214

相关论文

共 50 条

[31] CyclophosphamideMyelosuppression following off-label use: case report
Reactions Weekly, 2020, 1835 (1) : 116 - 116
[32] DenosumabHypocalcaemia following off-label use: case report
Reactions Weekly, 2022, 1923 (1) : 178 - 178
[33] DimeticoneGranuloma following off-label use: case report
Reactions Weekly, 2023, 1980 (1) : 150 - 150
[34] NalbuphineBradycardia following an off-label use: case report
Reactions Weekly, 2019, 1753 (1) : 255 - 255
[35] SildenafilHypotension following off-label use: case report
Reactions Weekly, 2025, 2045 (1) : 376 - 376
[36] DaratumumabHypogammaglobulinemia following off-label use: case report
Reactions Weekly, 2020, 1802 (1) : 114 - 114
[37] DapsoneMethaemoglobinaemia following off-label use: case report
Reactions Weekly, 2021, 1843 (1) : 130 - 130
[38] CyproteroneMeningiomas following off-label use: case report
Reactions Weekly, 2021, 1849 (1) : 152 - 152
[39] GlibenclamideHypoglycaemia following an off-label use : case report
Reactions Weekly, 2021, 1866 (1) : 190 - 190
[40] SintilimabFasciitis following off-label use: case report
Reactions Weekly, 2021, 1884 (1) : 391 - 391

← 1 2 3 4 5 →